Verona Pharma (VRNA) Competitors

Verona Pharma (NASDAQ:VRNA) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking.

Is VRNA or SMMT more profitable?

Verona Pharma's return on equity of -79.54% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verona Pharma	N/A	-79.54%	-43.49%
Summit Therapeutics	N/A	-85.42%	-52.66%

Which has more volatility and risk, VRNA or SMMT?

Verona Pharma has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.92, indicating that its stock price is 192% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of VRNA or SMMT?

85.9% of Verona Pharma shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 4.8% of Verona Pharma shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor VRNA or SMMT?

In the previous week, Summit Therapeutics had 4 more articles in the media than Verona Pharma. MarketBeat recorded 9 mentions for Summit Therapeutics and 5 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.06 beat Summit Therapeutics' score of 0.91 indicating that Verona Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verona Pharma	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has better valuation and earnings, VRNA or SMMT?

Verona Pharma has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma	$5.62M	595.86	-$54.37M	-$1.92	-21.70
Summit Therapeutics	$700K	19,563.44	-$614.93M	-$0.28	-66.32

Do analysts prefer VRNA or SMMT?

Verona Pharma currently has a consensus price target of $43.83, suggesting a potential upside of 5.22%. Summit Therapeutics has a consensus price target of $33.33, suggesting a potential upside of 79.50%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Verona Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
Summit Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the MarketBeat Community prefer VRNA or SMMT?

Verona Pharma received 22 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 80.55% of users gave Verona Pharma an outperform vote while only 58.22% of users gave Summit Therapeutics an outperform vote.

Company	Underperform	Outperform
Verona Pharma	Outperform Votes 323 80.55%	Underperform Votes 78 19.45%
Summit Therapeutics	Outperform Votes 301 58.22%	Underperform Votes 216 41.78%

Summary

Verona Pharma beats Summit Therapeutics on 12 of the 17 factors compared between the two stocks.